Orizuru Therapeutics

What Orizuru Therapeutics does

Orizuru Therapeutics, Inc. is a Japan-based regenerative medicine company developing iPS cell-derived cell therapies for severe heart failure (OZTx-556, using iPS cell-derived cardiomyocytes or iCM) and brittle Type 1 diabetes (OZTx-410, using iPS cell-derived pancreatic islet cells or iPIC). Founded in April 2021 by Kyoto University Innovation Capital as a spin-off of the T-CiRA joint research program between Kyoto University's Center for iPS Cell Research and Application (CiRA) and Takeda Pharmaceutical, the company commercializes two platform technologies developed during that collaboration, including a proprietary small-molecule compound purification method that removes non-target cells and a suspension culture system designed for scalable manufacturing. The company's two core product candidates, OZTx-410 and OZTx-556, are iPS cell-derived cell products manufactured using these proprietary differentiation, purification, and culture technologies, with OZTx-410 having reached investigator-initiated Phase 1/1b clinical evaluation at Kyoto University Hospital and first patient implantation completed in April 2025.

The company operates from Shonan Health Innovation Park in Fujisawa, Kanagawa (its main laboratory), with a registered head office in Kyoto, and is led by President and CEO Kenji Nonaka, M.D., Ph.D., with a Scientific Advisory Board chaired by Nobel laureate Shinya Yamanaka. Its business model is currently pre-commercial, with revenue expected to derive from one-time product sales of regenerative medicine cell therapy products upon regulatory approval, supplemented by professional services revenue from a Platform Innovation offering that uses iPS cell technologies to support drug discovery research for pharmaceutical and biotech customers. The go-to-market is enterprise field sales targeting academic medical institutions conducting investigator-initiated clinical trials, with manufacturing outsourced under GMP conditions to partners including S-RACMO for clinical trial material and Satake MultiMix and Toyo Seikan for large-scale culture systems.

To date, Orizuru Therapeutics has raised over JPY 10 billion in cumulative funding across seed, Series A, and Series B rounds (approximately JPY 6 billion in seed/Series A and JPY 3.3 billion in Series B in February 2024) plus AMED program grants, with strategic investors including Kyoto University Innovation Capital, Takeda Pharmaceutical, SMBC Venture Capital, MUFG Bank, MEDIPAL HOLDINGS, JDRF T1D Fund, and Japan Growth Capital Investment Corporation. The company is geographically concentrated in Japan and has not yet commercialized any products.

Name

Orizuru Therapeutics

Legal name

Orizuru Therapeutics, Inc.

Website

https://orizuru-therapeutics.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

51–100 employees

Short description

Orizuru Therapeutics is a Japan-based regenerative medicine company developing iPS cell-derived cell therapies OZTx-410 for brittle Type 1 diabetes and OZTx-556 for severe heart failure, leveraging proprietary purification and scalable culture technologies spun out from the T-CiRA collaboration between Kyoto University CiRA and Takeda Pharmaceutical.

Ownership category

akta.pro rank

Headquarters

HQ city

Fujisawa

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Regenerative medicine cell therapy products: Development and commercialization of iPS cell-derived cell therapy products (OZTx-410 for Type 1 diabetes, OZTx-556 for severe heart failure). Revenue will come from product sales upon regulatory approval.
2. iPS cell technology platform services: Drug discovery research support and regenerative medicine research infrastructure services using proprietary iPS cell technologies, including differentiation, culture, and purification technologies

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Orizuru Therapeutics develops and manufactures iPS cell-derived regenerative medicine products, primarily OZTx-410 (an iPS cell-derived pancreatic islet cell sheet for brittle Type 1 diabetes) and OZTx-556 (iPS cell-derived cardiomyocytes for severe heart failure). The company uses proprietary small-molecule compound-based purification, suspension culture systems, and subcutaneous implantation methods to produce high-purity, homogeneous cell therapy products. It also offers drug discovery research support and regenerative medicine research infrastructure services leveraging its iPS cell differentiation, culture, and purification expertise.

Product overview

Orizuru Therapeutics is a regenerative medicine company offering two primary cell therapy products derived from iPS cells: OZTx-410 (iPS cell-derived pancreatic islet cell sheet for brittle type 1 diabetes) and OZTx-556 (iPS cell-derived cardiomyocytes for severe heart failure). Both products utilize proprietary purification methods with small molecular compounds developed through the T-CiRA program with Kyoto University and Takeda Pharmaceutical. The company's technology platform encompasses iCM and iPIC products as well as platform innovation services supporting drug discovery research and regenerative medicine infrastructure using iPS cell technologies.

Differentiator

Problem solved

Functional benefit

Products and services

• OZTx-410 iPS cell-derived pancreatic islet cell sheet product for the treatment of brittle Type 1 diabetes. Manufactured using proprietary purification methods with small molecular compounds, consisting of safe, homogeneous, and high-purity pancreatic endocrine cell aggregates that exhibit physiological insulin secretion in response to glucose levels. Intended for Type 1 diabetes patients with recurrent severe hypoglycemia.
• OZTx-556 iPS cell-derived cardiomyocyte product for severe heart failure treatment. Manufactured using proprietary purification methods with small molecular compounds, featuring high engraftment capability and high purity for replenishing lost cardiomyocytes and promoting remuscularization. Intended for severe heart failure patients with limited therapeutic options.
• Platform Innovation Services Drug discovery research support and regenerative medicine research infrastructure development using proprietary iPS cell-related technologies, including differentiation, culture, and purification expertise. Supports iPSC-based research activities for academic institutions and pharmaceutical partners.

Quantifiable outcome

• Demonstrated engraftment of iPIC in immunocompromised diabetic minipig model with human C-peptide detection in blood
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Eleven partnerships are on record, tiered strategic and core.

• PeptiGrowth Inc.strategicStrategic or Co-development Partner · 22 August 2023Joint development contract to create synthetic peptide alternatives to recombinant growth factors used in manufacturing regenerative medicine products. Successfully developed alternative peptides in January 2025.
• Axcelead Drug Discovery Partners (Axcelead DDP)strategicTechnology or Integration · 10 March 2023Collaboration agreement for drug discovery support services using iPS cell-related technologies. Partnership enables Orizuru to offer iPS cell-based drug discovery services through Axcelead's platform.
• TechnoPro R&DstrategicStrategic or Co-development Partner · 7 March 2023Business partnership agreement for providing various services using iPS cell-related technologies for drug discovery research and regenerative medicine research outsourcing services.
• Satake MultiMix CorporationcoreTechnology or Integration · 26 April 2022Joint development of high-efficiency continuous single-use culture system (VMF-SUB/TCS) for stable large-scale culture of iPIC. System enables cultivation of hundreds of billions of cells with automatic control and perfused medium exchange under fully closed conditions.
• Toyo Seikan Group HoldingscoreTechnology or Integration · 15 April 2022Joint development of well bag system for large-scale production of homogeneous islet-like cell aggregates. Micro-well equipped culture bags enable scalable production of 650,000+ homogeneous iPIC clusters.
• S-RACMO Co., Ltd.coreImplementation/ SI/ Consulting Partner · 1 January 2022Contract manufacturing partner for OZTx-410 clinical trial products. S-RACMO manufactures investigational products at their GMP facility for the investigator-initiated clinical trial at Kyoto University Hospital.
• Takeda Pharmaceutical Company LimitedcoreStrategic or Co-development Partner · 10 August 2021Takeda Pharmaceutical partnered with Kyoto University CiRA through the 10-year T-CiRA joint research program with JPY 20 billion+ investment. T-CiRA program produced the two core technology platforms (iCM and iPIC) that were transferred to Orizuru Therapeutics. Takeda continues as a strategic partner and investor through Series B funding.
• Kyoto University iPS Cell Research Foundation (CiRA Foundation)coreStrategic or Co-development Partner · 10 August 2021Provides iPS cell stock as raw material for OZTx-410 products. Orizuru participates in the P.S. I LOVE YOU PROJECT led by the foundation for promoting iPS cell technology to society.
• Shonan Health Innovation Park (Shonan iPark)coreOthers · 10 August 2021Science park founded by Takeda Pharmaceutical in April 2018. Orizuru Therapeutics operates from Shonan iPark, which houses 120+ companies and organizations with 2,100+ workers forming a healthcare innovation ecosystem.
• Kyoto University HospitalcoreStrategic or Co-development Partner · 10 August 2021Conducting investigator-initiated Phase 1/1b clinical trial of OZTx-410 for Type 1 diabetes patients. First patient implantation performed in April 2025.
• Kyoto University iPS Cell Research Institute (CiRA)coreStrategic or Co-development Partner · 1 January 2015CiRA and Takeda launched T-CiRA joint research program in 2015. CiRA researchers Yoshinori Yoshida and Taro Toyoda led the iCM and iPIC projects that were spun out to Orizuru Therapeutics. Orizuru maintains licensing agreements with Kyoto University for IP and continues collaboration through scientific advisory board.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Heartseed: Japanese clinical-stage company developing iPSC-derived cardiomyocytes (HS-001) for severe heart failure. Directly comparable to Orizuru's OZTx-556 program in indication, modality, and geographic focus, making it the closest head-to-head peer.
• BlueRock Therapeutics: Bayer-owned iPSC-derived cell therapy developer with programs in Parkinson's disease, heart failure (iPSC-cardiomyocytes), and immunology. Uses engineered iPSC lines for allogeneic off-the-shelf therapies — directly comparable modality and overlapping heart-failure indication with OZTx-556.
• Vertex Pharmaceuticals (Cell Therapy / ViaCyte / Semma): Vertex acquired both ViaCyte and Semma Therapeutics to build a stem cell-derived islet cell therapy franchise for Type 1 diabetes (VX-880, VX-264). Directly comparable to OZTx-410 in indication and approach, with deeper capital and earlier-stage US clinical readouts.
• Fate Therapeutics: Clinical-stage US biotech developing iPSC-derived NK and T-cell immunotherapies. Comparable as an iPSC-platform cell therapy developer with proprietary differentiation/clonal master iPSC bank technology, though focused on oncology indications.
• Century Therapeutics: iPSC-derived allogeneic immune cell therapy developer (iNK and iT cells) for hematologic and solid tumors. Comparable platform technology (engineered iPSC lines, clonal master cell banks) and modality (off-the-shelf cellular therapy) to Orizuru, though in different indications.
• Megakaryon: Japanese iPSC-derived platelet developer advancing toward clinical trials for thrombocytopenia. Comparable as a Japanese iPSC-derived cell therapy company leveraging CiRA-adjacent iPSC technology, though targeting a different indication.

Broad incumbents

• Takeda Pharmaceutical: Originating T-CiRA partner and continuing strategic investor in Orizuru. Also operates a regenerative medicine unit with broader cell therapy programs and global commercialization capability — both a strategic enabler and a potential competitor/partner for iPSC-derived therapies.

Emerging players

• CytoPlex: iPSC-derived regenerative medicine developer referenced in cell therapy ecosystem coverage. Emerging player with partial overlap in iPSC-derived cell therapy space, though specific program details are limited.

Others

• S-RACMO: GMP contract manufacturing organization that manufactures OZTx-410 clinical trial products for Orizuru. Comparable as an enabling CDMO partner in the Japanese regenerative medicine manufacturing ecosystem, illustrating the outsourced manufacturing model Orizuru relies on.
• Kyoto University Innovation Capital (KYOTO-iCAP): Wholly-owned VC arm of Kyoto University that founded Orizuru and participated in seed/Series A/B rounds. Comparable as the founding financial and strategic partner providing the academic-to-commercial bridge for CiRA-originated iPSC technology companies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orizuru Therapeutics